A Phase 2 interventional study of Paltusotine in Acromegaly, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 26 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-17.
Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 2, Interventional, and Treatment
An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment regimens.
202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
This study's enrollment of 47 is close to the median of 43 across 115 interventional studies indexed under Acromegaly.
Browse Acromegaly studies →Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Paltusotine
Paltusotine, capsules, once daily by mouth
Also known as: CRN00808
Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level
Change from baseline in IGF-1 level at Week 13/End of Treatment (W13/EoT) in Group 1 subjects Efficacy Analysis Set (EAS).
Time frame: 13 Weeks
Proportion of Subjects With Their Last IGF-1 Measurement ≤ Upper Limit of Normal (ULN)
The secondary endpoint was the proportion of participants who maintained IGF-1 response, defined as the last assessment before the EoT with IGF-1 ≤1.0× ULN meet responder criteria, in Group 3, 4, and 5 subjects only at W13/EoT
Time frame: 13 Weeks
Proportion of Subjects With Their Last IGF-1 Measurements ≤1.5×ULN
Proportion of participants with IGF-1 ≤1.5× ULN at W13/EoT.
Time frame: 13 Weeks
A total of 45 subjects were planned to be enrolled in the study. 47 subjects participated in the study.
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Started | 25 | 10 | 5 | 4 | 3 |
| Completed | 25 | 10 | 5 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Started | 25 | 10 | 5 | 4 | 3 |
| Completed | 23 | 10 | 4 | 3 | 3 |
| Not completed | 2 | 0 | 1 | 1 | 0 |
| Withdrew: Prohibited medication | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Covid-19 lockdown | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Unable to travel | 1 | 0 | 0 | 0 | 0 |
| Milestone | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Started | 23 | 10 | 4 | 3 | 3 |
| Completed | 22 | 10 | 4 | 3 | 3 |
| Not completed | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 |
Change from baseline in IGF-1 level at Week 13/End of Treatment (W13/EoT) in Group 1 subjects Efficacy Analysis Set (EAS).
| ng/mL x ULN | Group 1 |
|---|---|
| Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level | -0.034 (-0.107 to 1.07) |
The secondary endpoint was the proportion of participants who maintained IGF-1 response, defined as the last assessment before the EoT with IGF-1 ≤1.0× ULN meet responder criteria, in Group 3, 4, and 5 subjects only at W13/EoT
| Participants | Group 3 | Group 4 | Group 5 |
|---|---|---|---|
| Baseline | 5 | 4 | 3 |
| W13/EoT (Response) | 2 | 1 | 1 |
| W13/EoT (No Response) | 3 | 3 | 2 |
Proportion of participants with IGF-1 ≤1.5× ULN at W13/EoT.
| Participants | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 |
|---|---|---|---|---|---|
| Baseline (Response) | 19 | 6 | 5 | 4 | 2 |
| W13/EoT (Response) | 20 | 4 | 4 | 3 | 1 |
| W13/EoT (No Response) | 5 | 6 | 1 | 1 | 2 |
Change from baseline in IGF-1 level at Week 13/End of Treatment (W13/EoT) in Group 1 subjects Efficacy Analysis Set (EAS).
| ng/mL x ULN | Group 1 |
|---|---|
| Baseline | 1.335 (1.078 to 1.471) |
| Week 13 (Visit 14)/ End of Treatment | 1.343 (1.169 to 1.448) |
Collected over Participants were monitored until the end of the 4-week follow-up period (up to 17 weeks total).. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose 5 mg | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Dose 10 mg | 0/47 (0%) | 0/47 (0%) | 23/47 (48.9%) |
| Dose 20 mg | 0/43 (0%) | 1/43 (2.3%) | 24/43 (55.8%) |
| Dose 30 mg | 0/37 (0%) | 0/37 (0%) | 15/37 (40.5%) |
| Dose 40 mg | 0/32 (0%) | 0/32 (0%) | 19/32 (59.4%) |
| Event | Dose 5 mg | Dose 10 mg | Dose 20 mg | Dose 30 mg | Dose 40 mg |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/2 | 0/47 | 1/43 | 0/37 | 0/32 |
| Event | Dose 5 mg | Dose 10 mg | Dose 20 mg | Dose 30 mg | Dose 40 mg |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/2 | 6/47 | 5/43 | 4/37 | 7/32 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/2 | 5/47 | 3/43 | 2/37 | 5/32 |
| FatigueGeneral disorders | 0/2 | 5/47 | 4/43 | 3/37 | 4/32 |
| ParesthesiaNervous system disorders | 0/2 | 3/47 | 5/43 | 2/37 | 3/32 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/2 | 5/47 | 4/43 | 0/37 | 2/32 |
| DiarrheaGastrointestinal disorders | 0/2 | 4/47 | 2/43 | 1/37 | 0/32 |
| Abdominal painGastrointestinal disorders | 0/2 | 4/47 | 1/43 | 0/37 | 0/32 |
| Peripheral swellingGastrointestinal disorders | 0/2 | 3/47 | 2/43 | 1/37 | 2/32 |
| Abdominal distensionGastrointestinal disorders | 0/2 | 3/47 | 0/43 | 0/37 | 0/32 |
| DyspepsiaGastrointestinal disorders | 0/2 | 1/47 | 1/43 | 1/37 | 2/32 |
Of the 47 participants who received CRN00808-03, 42 participants completed the trial, 4 participants withdrew from treatment period, and 1 participant withdrew consent during follow up. No participants withdrew due to adverse events.
| Age, Categorical(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 22 | 8 | 4 | 3 | 2 | 39 |
| >=65 years | 3 | 2 | 1 | 1 | 1 | 8 |
| Age, Customized(years) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| Age, y, median (range) | 52.0 (31 to 71) | 52.5 (31 to 70) | 51.0 (43 to 69) | 56.0 (46 to 67) | 38.0 (35 to 66) | 51.0 (31 to 71) |
| Sex: Female, Male(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| Female | 11 | 7 | 3 | 3 | 3 | 27 |
| Male | 14 | 3 | 2 | 1 | 0 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 6 | 2 | 0 | 1 | 13 |
| Not Hispanic or Latino | 21 | 4 | 3 | 4 | 2 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| White | 25 | 5 | 5 | 4 | 3 | 42 |
| Asian | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 2 | 0 | 0 | 0 | 2 |
| Other | 0 | 2 | 0 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| United States | 3 | 1 | 0 | 2 | 2 | 8 |
| Germany | 0 | 1 | 0 | 0 | 0 | 1 |
| Greece | 5 | 0 | 0 | 1 | 0 | 6 |
| Hungary | 5 | 1 | 0 | 0 | 0 | 6 |
| Italy | 0 | 0 | 1 | 0 | 0 | 1 |
| Poland | 2 | 0 | 0 | 0 | 0 | 2 |
| Romania | 0 | 0 | 0 | 1 | 1 | 2 |
| Serbia | 3 | 0 | 0 | 0 | 0 | 3 |
| Slovakia | 1 | 0 | 0 | 0 | 0 | 1 |
| United Kingdom | 2 | 0 | 0 | 0 | 0 | 2 |
| Brazil | 4 | 6 | 3 | 0 | 0 | 13 |
| New Zealand | 0 | 1 | 1 | 0 | 0 | 2 |
| Height(centimeter) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| Median | 173.95 (166.50 to 178.50) | 167.75 (160.00 to 173.00) | 173.00 (164.00 to 176.00) | 169.45 (168.45 to 179.65) | 157.50 (155.50 to 169.00) | 170.25 (165.00 to 176.10) |
| Weight(kilogram(s)) | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Total |
|---|---|---|---|---|---|---|
| Median | 90.95 (76.05 to 103.60) | 84.95 (75.00 to 117.00) | 87.30 (79.70 to 88.20) | 107 (88.75 to 114.35) | 77.50 (59 to 82.40) | 87.15 (75.10 to 104.20) |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Aug 2020, 16 months.
Results were first posted in Feb 2025, 4 years 6 months after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paltusotine
Crinetics Pharmaceuticals Inc. →